ArticleOncoimmunology2025

Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases.

Vasiliki Anastasopoulou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.